Products
Online Inquiry
Our Products Cannot Be Used As Medicines Directly For Personal Use.
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
MK-5172 sodium salt
Cat No.
CEI-1430
Product Overview
IC50 Value: 7.4nM and 7nM for genotype1b and 1a respectively, in replicon system. MK-5172 is a novel P2-P4 quinoxaline macrocyclic HCV NS3/4a protease inhibitor currently in clinical development. Clinical trial: Evaluation of Hepatic Pharmacokinetics for MK-5172 in Participants With Chronic Hepatitis C. Phase1
CAS No.
1425038-27-2
Molecular Weight
789.89
Storage
Store at -20°C
Synonyms
MK5172 sodium salt; MK 5172 sodium salt
Targets
HCV NS3/4a protease
Molecular Formula
C38H50N6NaO9S+
Solubility
Soluble in DMSO
Shipping Conditions
Evaluation sample solution: ship with blue ice. All other available size: ship with RT, or blue ice upon request
In vitro
In biochemical assays, MK-5172 was effective against a panel of major genotypes and variants engineered with common resistant mutations observed in clinical studies with other NS3/4a protease inhibitors. In the replicon assay, MK-5172 demonstrated subnanomolar to low-nanomolar EC50s against genotypes 1a, 1b, and 2a.
In vivo
In rats, MK-5172 showed a plasma clearance of 28 ml/min/kg and plasma half-life of 1.4 hr. When dosed p. o. at 5 mg/kg, the plasma exposure of MK-5172 was good with an AUC of 0.7 uM. hr. The liver exposure of the compound was quite good (23 uM at 4 hr), and MK-5172 remained in liver 24 hr after a single p. o. 5 mg/kg dose. At 24 hr, the liver concentration of MK-5172 was 0.2 uM, which was over 25-fold higher than the IC50 in the replicon assay with 50% NHS. When dosed to dogs, MK-5172 showed low clearance of 5 ml/min/kg and a 3 hr half-life after i. v. 2 mg/kg dosing and had good plasma exposure (AUC=0.4 uM. hr) after a p. o. 1 mg/kg dose.
Download
Download Datasheet